CommercialPrior AuthMedium impact
Inbrija® (inhaled levodopa) (Revised)
Humana·Neurology, Geriatrics, Internal Medicine·Commercial
Effective date
Mar 27, 2024
We identified it
Jun 25, 2026
Summary
Humana revised its Inbrija® (inhaled levodopa) prior authorization policy effective March 27, 2024. The policy maintains existing prior authorization requirements for commercial plans covering this medication for Parkinson's disease 'off' episodes. Billing teams must verify all four approval criteria are met before claims are submitted to avoid denials.
Action Required
By April 15, 2024: Billing team must update internal prior authorization checklists and EMR templates to reflect the current Humana Inbrija policy. Ensure providers document that patients meet ALL four criteria before submitting claims: (1) confirmed Parkinson's disease diagnosis, (2) current concurrent use of carbidopa/levodopa, (3) documented breakthrough 'off' periods, and (4) prior trial or contraindication to both a dopamine agonist AND either an MAO-B inhibitor or COMT inhibitor. Prior authorization must be obtained before dispensing—claims submitted without approval will be denied. Update internal policy files and remove any outdated versions. Verify the current version at http://apps.humana.com/tad/tad_new/home.aspx before processing any Inbrija requests for Humana commercial members.